# BioSig Technologies signs agreement with Texas Cardiac Arrhythmia Institute for first-in-human studies

BioSig Technologies signed an agreement with Texas Cardiac Arrhythmia Institute to conduct first-in-human studies using the PURE EP System at St. David's Medical Center in Austin, Texas.

- Type: Contract
- Announced: 2018-11-27
- Where: Austin, Texas, United States
- Status: announced
- Products: PURE EP System
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [BioSig Technologies](https://endata.com/companies/35722.md)
- [Texas Cardiac Arrhythmia Institute](https://endata.com/companies/35723.md) (partner)

## Sources

- [financialnewsmedia.com](https://www.financialnewsmedia.com/biosig-technologies-signs-agreement-with-texas-cardiac-arrhythmia-institute-for-first-in-human-studies/), 2018-11-27: "BioSig Technologies, Inc. today announced that the Company has signed an agreement with Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center in Austin, Texas to conduct First-in-Human studies using the PURE EP™ System."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.